Fizazi, et al. ARAMIS: Efficacy and safety of darolutamide in nonmetastatic castration-resistant prostate cancer (nmCRPC). ASCO-GU 2019, abstract 140.
Cemiplimab bij gemetastaseerd basaalcelcarcinoom na hedgehog pathway inhibitors
apr 2024 | Dermato-oncologie, Immuuntherapie